Health outcomes among patients diagnosed with schizophrenia in the US veterans health administration population who transitioned from once-monthly to once-every-3-month Paliperidone Palmitate: an observational retrospective analysis
MetadataShow full item record
CitationPatel, C., El, K. A., Huang, A., Wang, L., Baser, O., & Joshi, K. (August 08, 2019). Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy. 1-13.
There is limited literature on treatment patterns, healthcare resource utilization (HRU), and costs among patients who transition from once-monthly paliperidone palmitate (PP1M) to once-every-3-month paliperidone palmitate (PP3M) in a real-world setting. Hence, this study compared treatment patterns, HRU, and costs 12-month pre- and post-PP3M transition among Veteran’s Health Administration (VHA) patients with schizophrenia.